Previous close | 47.83 |
Open | 47.82 |
Bid | 48.97 x N/A |
Ask | 48.98 x N/A |
Day's range | 46.80 - 49.90 |
52-week range | 32.10 - 62.90 |
Volume | |
Avg. volume | 10,465,047 |
Market cap | 29.441B |
Beta (5Y monthly) | 1.61 |
PE ratio (TTM) | 73.09 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 0.20 (0.42%) |
Ex-dividend date | 18 June 2024 |
1y target est | N/A |
Gan & Lee Pharmaceuticals (Gan & Lee, Shanghai Stock Exchange: 603087) announced the results of the Phase 1b/2a clinical study of the Company's independently developed glucagon-like peptide-1 (GLP-1) receptor agonist, GZR18 Injection, in an obese/overweight population in China, along with the results of two other innovative insulins' preclinical studies in poster presentations at the American Diabetes Association's(ADA's)84th Scientific Sessions.
Gan & Lee Pharmaceuticals (Shanghai Stock Exchange: 603087) announced today the presentation of three abstracts featuring their investigational products at the American Diabetes Association's (ADA's[1]) 84th Scientific Sessions. The meeting will be held in-person and virtually from June 21-24, 2024, in Orlando, Florida .